Table 3.

Baseline characteristics of patients with VT/VF compared to those without VT/VF in individuals undergoing L5 measurement.

Variables	VT/VF (n = 21)	No VT/VF (n = 46)	P-value
Age (year)	53.27 ± 7.38	54.78 ± 11.30	0.678
Men	21 (100)	43 (91.3)	0.301
Body mass index	31.05 ± 10.85	27.28 ± 6.92	0.163
Current smoker	13 (61.9)	29 (63.0)	1.000
Hypertension	9 (42.9)	27 (58.7)	0.294
Diabetes mellitus	6 (28.6)	16 (34.8)	0.781
Hyperlipidemia	2 (9.5)	5 (10.9)	1.000
Chronic kidney diseases	0 (0)	2 (4.3)	0.563
End-stage renal disease	0 (0)	1 (2.2)	1.000
Chronic obstructive pulmonary diseases	0 (0)	1 (2.2)	1.000
Prevalent/incident atrial fibrillation	0 (0)	0 (0)	1.000
History of Cerebral vascular accident	0 (0)	0 (0)	1.000
Total cholesterol (mg/dl)	162.7 ± 43.62	186.56 ± 43.90	0.131
Triglyceride (mg/dl)	154,09 ± 97.33	179.85 ± 170.11	0.635
LDL (mg/dl)	95.19 ± 43.71	114.95 ± 37.39	0.142
HDL (mg/dl)	45.52 ± 23.74	39.42 ± 12.51	0.258
Peak troponin I (ng/ml)	88.02 ± 106.82	26.10 ± 23.12	0 . 004
Culprit vessel
Left anterior descending	18 (85.7)	33 (71.7)	0.240
Left circumflex	8 (38.1)	23 (50.0)	0.434
Right coronary artery	11 (52.4)	33 (71.7)	0.167
Killip class			<0.001
1	0 (0)	40 (87.0)
2	2 (9.5)	1 (2.2)
3	2 (9.5)	0 (0)
4	17 (81.0)	5 (10.8)
Left ventricular ejection fraction (%)	41.97 ± 14.30	52.46 ± 14.84	0.044
In-hospital MACE	0 (0)	0 (0)	1.000
Post-PCI TIMI flow			0.622
0	0 (0)	1 (2.2)
1	2 (9.5)	1 (2.2)
2	1 (4.8)	1 (2.2)
3	18 (85.7)	43 (93.4)

Data are expressed as the mean ± SD and n (%). ALT, Alanine Transaminase; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; MACE, major adverse cardiac events; TIMI, thrombolysis In myocardial infarction; VT/VF, ventricular tachycardia/ventricular fibrillation.

The bold values indicates statistical significance.